LONDON, ENGLAND / ACCESSWIRE / August 8, 2016 / GW Pharmaceuticals plc (NASDAQ: GWPH) will host a conference call and live webcast to discuss the results of the third quarter 2016, to be held Tuesday, August 9, 2016 at 8:30 AM Eastern Time.

You can listen to the event online at www.investorcalendar.com/IC/CEPage.asp?ID=175231 or on the GW Pharmaceuticals website (www.gwpharm.com).

If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or www.gwpharm.com.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, LGS and Tuberous Sclerosis Complex. GW successfully commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit http://www.gwpharm.com.

SOURCE: Investor Calendar